News | Myriad Genetics

GeneSight Psychotropic Test’s Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood Levels

Products

Myriad Genetics Launches New Vectra® Cardiovascular Risk Assessment for Patients with Rheumatoid Arthritis

Products

Myriad Genetics Receives Reimbursement for BRACAnalysis® Diagnostic System in Japan

Products

Myriad Genetics Forms Strategic Partnership with Illumina in Oncology

Products

Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment with Zejula®

Products

New Study Provides Personalized Breast Cancer Risk Information for Women with ATM Gene Mutations

Pipeline

Suffering in Silence: Two-Thirds of Older Adults Say They Won’t Treat Their Depression

Products

Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China

Pipeline

New Data Show Importance of Vectra® Testing and Biomarkers in Predicting Risk for Cardiovascular Events in Patients with Rheumatoid Arthritis

Pipeline

German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test

Pipeline

American Society of Clinical Oncology Exclusively Cites myChoice® CDx in New Recommendations for Patients with Advanced Ovarian Cancer

Pipeline

New Study Shows Screening Based on Self-Reported Ethnicity Fails to Identify Significant Percentage of Pregnancies Affected by Serious Genetic Conditions

Pipeline

Medicare Expands Coverage for BRACAnalysis® CDx in Prostate Cancer

Pipeline

Myriad Launches Proprietary AMPLIFY™ Technology, Further Increasing the Performance of its Prequel™ NIPS Test

Pipeline

Myriad Announces the Launch of a New Radiographic Progression Prognostic Tool, Adding to Clinical Value of Vectra®

Pipeline